GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ginkgo Bioworks Holdings Inc (NYSE:DNA) » Definitions » Change In Receivables

Ginkgo Bioworks Holdings (Ginkgo Bioworks Holdings) Change In Receivables : $50.1 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Ginkgo Bioworks Holdings Change In Receivables?

Ginkgo Bioworks Holdings's change in receivables for the quarter that ended in Dec. 2023 was $28.9 Mil. It means Ginkgo Bioworks Holdings's Accounts Receivable declined by $28.9 Mil from Sep. 2023 to Dec. 2023 .

Ginkgo Bioworks Holdings's change in receivables for the fiscal year that ended in Dec. 2023 was $50.1 Mil. It means Ginkgo Bioworks Holdings's Accounts Receivable declined by $50.1 Mil from Dec. 2022 to Dec. 2023 .

Ginkgo Bioworks Holdings's Accounts Receivable for the quarter that ended in Dec. 2023 was $17.9 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Ginkgo Bioworks Holdings's Days Sales Outstanding for the three months ended in Dec. 2023 was 46.99.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Ginkgo Bioworks Holdings's liquidation value for the three months ended in Dec. 2023 was $389.3 Mil.


Ginkgo Bioworks Holdings Change In Receivables Historical Data

The historical data trend for Ginkgo Bioworks Holdings's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ginkgo Bioworks Holdings Change In Receivables Chart

Ginkgo Bioworks Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
-1.84 -14.23 -114.09 55.02 50.07

Ginkgo Bioworks Holdings Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.50 -0.53 15.92 5.77 28.90

Ginkgo Bioworks Holdings Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $50.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ginkgo Bioworks Holdings  (NYSE:DNA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Ginkgo Bioworks Holdings's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=17.899/34.755*91
=46.99

2. In Ben Graham's calculation of liquidation value, Ginkgo Bioworks Holdings's accounts receivable are only considered to be worth 75% of book value:

Ginkgo Bioworks Holdings's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=944.073-568.19+0.75 * 17.899+0.5 * 0.046
=389.3

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ginkgo Bioworks Holdings Change In Receivables Related Terms

Thank you for viewing the detailed overview of Ginkgo Bioworks Holdings's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Ginkgo Bioworks Holdings (Ginkgo Bioworks Holdings) Business Description

Traded in Other Exchanges
Address
27 Drydock Avenue, 8th Floor, Boston, MA, USA, 02210
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Foundry and Biosecurity. The Biosecurity segment generates the majority of revenue.
Executives
Jason R Kelly director, officer: CEO & Founder 667 MADISON AVENUE, C/O CORVEX MANAGEMENT LP, NEW YORK NY 10065
Mark E. Dmytruk officer: Chief Financial Officer C/O SOARING EAGLE ACQUISITION CORP., 955 FIFTH AVENUE, NEW YORK NY 10075
Barry Canton 10 percent owner C/O GINKGO BIOWORKS, INC., 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Reshma P. Shetty director, 10 percent owner, officer: President, COO & Founder C/O SOARING EAGLE ACQUISITION CORP., 955 FIFTH AVENUE, NEW YORK NY 10075
Christian O Henry director 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Harry Sloan director, officer: CEO, Chairman 1450 2ND STREET, SUITE 247, SANTA MONICA CA 90401
Shyam Sankar director C/O PALANTIR TECHNOLOGIES INC., 1200 17TH STREET, FLOOR 15, DENVER CO 80202
Steven P. Coen officer: Chief Accounting Officer C/O GINKGO BIOWORKS HOLDINGS, INC., 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Marie E. Fallon officer: Chief Accounting Officer C/O GINKGO BIOWORKS, INC., 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Marijn E Dekkers director GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210
Kathy Hopinkah Hannan director ANNALY CAPITAL MANAGEMENT, INC., 1211 AVE. OF THE AMERICAS, NEW YORK NY 10036
David C. Ott 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc 10 percent owner 55 RAILROAD AVENUE, GREENWICH CT 06830